Join the Durvalumab group to help and get support from people like you.
Durvalumab News
An Artificial Sweetener May Hamper Immunotherapy Cancer Treatment
MONDAY, Aug. 4, 2025 — Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Immunotherapy Effective Against Stomach Cancer
FRIDAY, June 6, 2025 — Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says. People treated with durvalumab and c...
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 – For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better...
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant...
Radiotherapy With Adjuvant Durvalumab No Benefit for Head, Neck Cancer
MONDAY, Dec. 9, 2024 – For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cisplatin, radiotherapy with adjuvant durvalumab does not...
Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer
5 December 2024 – AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not p...
There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin
TUESDAY, Nov. 26, 2024 – Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial...
Imfinzi Approved in the US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery
16 August 2024 – AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small c...
Imfinzi and Imjudo with Chemotherapy Approved in the US for Patients with Metastatic Non-Small Cell Lung Cancer
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy 11 November 2022 – AstraZeneca’s I...
Imfinzi Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
On September 2, 2022, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or...
Imfinzi Approved in the US for Less-Frequent, Fixed-Dose Use
20 November 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable ...
Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
30 March 2020 – AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with sta...
FDA Approves Imfinzi (durvalumab) for Unresectable Stage III Non-Small Cell Lung Cancer
February 16, 2018 – The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not...
AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
May 1, 2017 – AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi...
Further information
Related condition support groups
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Endometrial Cancer, Hepatocellular Carcinoma